HEALTH CARE RESOURCE UTILIZATION (HCRU) OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NIVOLUMAB VERSUS DOCETAXEL: RESULTS FROM THE CHECKMATE 078 (CM078) TRIAL

被引：0
|
作者：
Lawrance, R. [1 ]
DeRosa, M. [2 ]
Taylor, F. [2 ]
Penrod, J. R. [3 ]
Shaw, J. W. [4 ]
Wang, P. F. [5 ]
机构：
[1] Adelphi Values, Bollington SK10 5JB, Cheshire, England
[2] Adelphi Values, Boston, MA USA
[3] Bristol Myers Squibb Co, Princeton, NJ USA
[4] Bristol Myers Squibb Co, Lawrenceville, NJ USA
[5] BMS, Jamison, PR USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.247
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN123
引用
收藏
页码：S79 / S79
页数：1
相关论文
共 50 条
  • [21] Impact of baseline serum cytokines on survival in patients (pts) with advanced squamous (SO) non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) or docetaxel (doc): Exploratory analyses from CheckMate 063 and CheckMate 017
    Farsaci, Benedetto
    Geese, William J.
    Desai, Kaushal D.
    Jin, Chelsea
    Antonia, Scott J.
    Lena, Herve
    Horn, Leora
    Planchard, David
    Reckamp, Karen L.
    Stinchcombe, Thomas E.
    Gettinger, Scott
    Borghaei, Hossein
    Hellmann, Matthew D.
    Harbison, Christopher
    Xu, Dong
    Blackwood-Chirchir, M. Anne
    Rizvi, Naiyer
    CANCER RESEARCH, 2016, 76
  • [22] SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC)
    Borghaei, H.
    Johnson, M. L.
    Garon, E. B.
    He, K.
    Planchard, D.
    Reck, M.
    Popat, S.
    Herbst, R. S.
    Leal, T. A.
    Dumoulin, D.
    De Marinis, F.
    Reynolds, C. H.
    Theelen, W. S. M. E.
    Percent, I.
    Calderon, V. Gutierrez
    Flandin, A. C. Madroszyk
    Shazer, R. L.
    Yan, X.
    Harrigan, R.
    Peters, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1308 - S1308
  • [23] LONG-TERM HEALTHCARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH PATIENTS TREATED WITH NIVOLUMAB FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Grumberg, V
    Cotte, F. E.
    Jouaneton, B.
    Jolivel, R.
    Corre, R.
    Giaj-Levra, M.
    Gaudin, A. F.
    Calvet, C. Y.
    Assie, J. B.
    Chouaid, C.
    VALUE IN HEALTH, 2020, 23 : S484 - S484
  • [24] Checkmate 384: A Phase 313/4 Dose Frequency Optimization Trial of Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Harris, Ronald
    Reinmuth, Niels
    Mitche, Paul
    Zhu, Jin
    Chang, I-Fen
    Pichons, Eric
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1298 - S1299
  • [25] Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153
    Spigel, David
    Schwartzberg, Lee
    Waterhouse, David
    Chandler, Jason
    Hussein, Maen
    Jotte, Robert
    Stepanski, Edward
    Mccleod, Michael
    Page, Ray
    Sen, Rohini
    Mcdonald, Jeffrey
    Bennett, Kelly
    Korytowsky, Beata
    Aanur, Nivedita
    Reynolds, Craig
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1287 - S1288
  • [26] Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
    Qiao Liu
    Xia Luo
    Liubao Peng
    Lidan Yi
    Xiaomin Wan
    Xiaohui Zeng
    Chongqing Tan
    Clinical Drug Investigation, 2020, 40 : 129 - 137
  • [27] Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
    Liu, Qiao
    Luo, Xia
    Peng, Liubao
    Yi, Lidan
    Wan, Xiaomin
    Zeng, Xiaohui
    Tan, Chongqing
    CLINICAL DRUG INVESTIGATION, 2020, 40 (02) : 129 - 137
  • [28] Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
    Vokes, E. E.
    Ready, N.
    Felip, E.
    Horn, L.
    Burgio, M. A.
    Antonia, S. J.
    Frontera, O. Aren
    Gettinger, S.
    Holgado, E.
    Spigel, D.
    Waterhouse, D.
    Domine, M.
    Garassinoio, M.
    Chow, L. Q. M.
    Blumenschein, G., Jr.
    Barlesi, F.
    Coudert, B.
    Gainor, J.
    Arrieta, O.
    Brahmer, J.
    Butts, C.
    Steins, M.
    Geese, W. J.
    Li, A.
    Healey, D.
    Crino, L.
    ANNALS OF ONCOLOGY, 2018, 29 (04) : 959 - 965
  • [29] Long-term outcomes with nivolumab in patients with previously treated advanced Non-Small Cell Lung Cancer (NSCLC)
    Thomas, M.
    Kohlhaeufl, M.
    Reck, M.
    Engel-Riedel, W.
    Kortsik, C.
    Bullinger, L.
    Schneider, C. -P.
    Felip, E.
    Brahmer, J.
    Vokes, E.
    Gettinger, S.
    Geese, W.
    Yoon, D.
    Healey, D.
    Li, A.
    Eberhardt, W. E. E.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 137 - 137
  • [30] Cobolimab with Dostarlimab and Docetaxel in Patients with Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung
    Kim, H. R.
    Gridelli, C.
    Kapur, D.
    Tufman, A.
    Felip, E.
    Velcheti, V.
    Kim, Y. J.
    Goetze, T. O.
    Lopez, P. Garrido
    Corre, R.
    Penkov, K.
    Anjum, R.
    Di Pace, B.
    Liu, W.
    Borgovan, T.
    Ledger, D.
    Carver, J.
    Waszak, A.
    Dhar, A.
    Novello, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S109 - S110
12345